(Q34563883)

3 August 2017

title

Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics (English)

1 reference

3 August 2017

1 reference

1 reference

Scott W Grimm

1

1 reference

3 August 2017

Neil M Richtand

2

1 reference

3 August 2017

Helen R Winter

3

1 reference

3 August 2017

Karen R Stams

4

1 reference

3 August 2017

Stots B Reele

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

British Journal of Clinical Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

61

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

58-69

1 reference

A study of quetiapine: efficacy and tolerability in psychotic adolescents

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Interaction of common azole antifungals with P glycoprotein

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Drug metabolism and atypical antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Systemic antifungal agents. Drug interactions of clinical significance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Clinically significant drug interactions with new immunosuppressive agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884989

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

7 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02507.X

The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02507.X

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02507.X

Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02507.X

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02507.X

Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes

21 January 2018

1 reference

12 December 2020

Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole

1 reference

12 December 2020

Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase

1 reference

12 December 2020

Quetiapine, an atypical antipsychotic

1 reference

12 December 2020

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole

1 reference

12 December 2020

10.1111/J.1365-2125.2005.02507.X

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference